

September 22, 2015



# Corbus Pharmaceuticals to Present Additional Data on the Effects of Resunab(TM) in the Treatment of Pulmonary Infection and Inflammation in Pre-Clinical Models of Cystic Fibrosis

**Data to Be Presented at the North American Cystic Fibrosis Conference October 8-10, 2015; Resunab Demonstrated Improvement in Lung Inflammation and Infection in Cystic Fibrosis Pre-Clinical Model**

NORWOOD, MA -- (Marketwired) -- 09/22/15 -- [Corbus Pharmaceuticals Holdings, Inc.](#) (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that it will present additional data on the effects of [Resunab™](#) in the cystic fibrosis ("CF") transmembrane conductance regulator ("CFTR") deficient mouse model at the [North American Cystic Fibrosis Conference](#) ("NACFC") being held October 8-10, 2015 in Phoenix, Arizona.

Tracey L. Bonfield Ph.D., Associate Professor, Department of Pediatrics, Case Western Reserve University, will present results from the CF murine model of infection and inflammation study being conducted with Resunab. The poster entitled, "[Resunab, a CB2 Agonist for the Treatment of CF,](#)" will provide further data demonstrating the benefit of Resunab in treating CF lung infection and inflammation in this model.

"Pulmonary infection and inflammation are major contributors to the morbidity and mortality in CF," stated Mark A. Tepper, Ph.D., President and Chief Scientific Officer of the Company. "Despite the great strides that have been made in the development of specific CFTR-targeted therapeutics, there is significant unmet need to target the inflammation that begins to damage the lungs from an early age in CF. Resunab is a novel drug that acts to stimulate the production of specialized pro-resolving mediators with the potential to be an effective treatment for the inflammation and fibrosis associated with CF, as well as to provide a benefit in treating the chronic lung infections so prevalent in this debilitating rare disease."

The Company previously reported [positive data on the effects of Resunab™ in the resolution of lung inflammation, reduction of bacterial load, and improvement of survival in a CFTR-deficient mouse model](#) from a study being conducted at the Cystic Fibrosis Foundation Anti-Inflammatory Pre-Clinical Modeling Core Center, Pediatrics at Case Western Reserve

University in Cleveland, Ohio, in collaboration with Corbus.

"The ongoing studies being conducted in the CF murine model at Case Western continue to support the potential of Resunab to treat CF through its novel mechanism of inflammatory resolution," stated Dr. Bonfield. "The initial data we reported was very encouraging, and I look forward to presenting additional supportive data on the positive effects of Resunab in CF at NACFC in October."

Sponsored by the Cystic Fibrosis Foundation, the North American Cystic Fibrosis Conference is one of the largest forums to advance CF drug development, research and care.

### ***About Cystic Fibrosis***

Cystic Fibrosis ("CF") is a chronic, life-threatening, genetic disease caused by inheriting two dysfunctional CFTR genes that normally regulate salt and water movement across cells in the respiratory and digestive systems. People with CF have thick, sticky mucus that clogs their airways, with recurrent bacterial infections and chronic inflammation in their lungs. In the gastrointestinal tract, they also have mucus accumulation, bacterial overgrowth, and inflammation. The dysfunctional CFTR genes cause an exaggerated inflammatory response that compounds the damage from a coexisting infection in the lungs and gut. CF results in destruction of lung tissue, lung fibrosis, pancreatic insufficiency, CF-related diabetes, malabsorption, malnutrition, growth retardation, and liver disease, including cirrhosis. The harmful inflammation and accompanying fibrosis in CF damages multiple organs, impairs organ function, reduces health-related quality of life and can lead to death.

### ***About Resunab<sup>™</sup>***

Resunab<sup>™</sup> is a novel synthetic oral endocannabinoid-mimetic drug that preferentially binds to the CB2 receptor expressed on activated immune cells and fibroblasts. CB2 activation triggers endogenous pathways that resolve inflammation and halt fibrosis. Pre-clinical and Phase 1 studies have shown Resunab to have a favorable safety, tolerability and pharmacokinetic profile. It has also demonstrated promising potency in pre-clinical models of inflammation and fibrosis. Resunab triggers the production of "Specialized Pro-resolving Lipid Mediators" that activate an endogenous cascade responsible for the resolution of inflammation and fibrosis, while reducing production of pro-inflammatory eicosanoids and cytokines. Resunab has direct effects on fibroblasts to halt tissue scarring. In effect, Resunab triggers endogenous pathways to turn "off" chronic inflammation and fibrotic processes, without causing immunosuppression.

### ***About Corbus***

Corbus Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. Our lead product candidate, Resunab<sup>™</sup>, is a novel synthetic oral endocannabinoid-mimetic drug that resolves chronic inflammation, bacterial infections, and fibrotic processes. Resunab is currently in Phase 2 studies for the treatments of cystic fibrosis, diffuse cutaneous systemic sclerosis and skin-predominant dermatomyositis.

For more information, please visit [www.CorbusPharma.com](http://www.CorbusPharma.com) and connect with the Company on [Twitter](#), [LinkedIn](#), [Google+](#) and [Facebook](#).

### ***Forward-Looking Statements***

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

### ***Investor Contact***

Jenene Thomas  
Jenene Thomas Communications, LLC  
Phone: +1 (908) 938-1475  
Email: [Email Contact](#)

### ***Media Contact***

David Schull or Marissa Goberdhan  
Russo Partners, LLC  
Phone: +1 (858) 717-2310  
Email: [Email Contact](#)  
Email: [Email Contact](#)

Source: Corbus Pharmaceuticals Holdings, Inc.